CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that the company will participate in two upcoming investor conferences:
On Friday, March 23, 2018, at 11:30 a.m. ET, Michael Gilman, Ph.D., Chief Executive Officer, will present a company overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, NY. A breakout session will follow the presentation at 12:00 noon.
On Tuesday, April 3, 2018, Dr. Gilman will also make a presentation on Obsidian at 3:15 p.m. ET at the Jefferies IO Cell Therapy Summit, an event focused on novel therapeutics in the immuno-oncology space, at the Boston Harbor Hotel in Boston.
About Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian’s lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors. The company is headquartered in Cambridge, Massachusetts. Please visit www.obsidiantx.com.